# A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

> **NCT02109016** · PHASE2 · TERMINATED · sponsor: **Clovis Oncology, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer
- Squamous Non-Small Cell Lung Cancer
- NSCLC
- Small Cell Lung Cancer
- SCLC
- Lung Cancer
- Advanced Lung Cancer
- Metastatic Lung Cancer
- Stage IV Lung Cancer

## Interventions

- **DRUG:** Lucitanib

## Key facts

- **NCT ID:** NCT02109016
- **Lead sponsor:** Clovis Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-04-01
- **Final completion:** 2016-09
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02109016

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02109016, "A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02109016. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*